GenTide Biopharmaceutical is an international innovative drug enterprise powered by an AI Bio-Large Model Platform. We integrate AI with Cryo-EM structural biology to discover first-in-class therapies in metabolic disease, pain, oncology, and aging. 睿联生物医药是一家以AI生物大模型平台为核心发动机的国际化创新药企业。 我们深度融合人工智能与冷冻电镜结构生物学，在代谢疾病、疼痛管理、 肿瘤治疗与抗衰老领域开发 first-in-class 创新药。
Explore the Platform 了解技术平台 View Pipeline 查看研发管线Our AI-driven DTBL closed-loop compresses drug discovery timelines while improving the chances of delivering a viable clinical candidate. 我们的 AI 驱动的 DTBL 研发闭环大幅缩短新药发现周期， 同时显著提升临床前候选化合物的命中率与成药性。
10+ core algorithms and a 10M+ compound library drive source-innovation and a high-druggability chemical space. 10+ 核心算法与千万级分子库，驱动源头创新， 构建高成药性化学空间。
Novel PAGln/PAA pro-aging mechanism backed by Nature Aging publications and proprietary p16 reporter mice. 揭示全新 PAGln/PAA 促衰老致病机制， 发表于 Nature Aging，依托独家 p16 报告基因小鼠。
Seamless dry-wet experiment synergy solves the high trial-and-error cost of traditional drug discovery. 干湿实验无缝协同，破局传统新药发现试错成本极高的行业痛点。
US / Singapore / China global layout with full NMPA + FDA dual IND filing capability. 美国 / 新加坡 / 中国全球布局， 具备 NMPA 与 FDA 中美双报核心能力。
GLP-1R / GIPR / GCGR tri-agonist for metabolic disease and obesity. GLP-1R / GIPR / GCGR 三靶点激动剂，靶向代谢疾病与肥胖。
Nav1.8 selective inhibitor — safer pain management without addiction risk. Nav1.8 选择性抑制剂，消除成瘾风险的安全镇痛方案。
MET / RET / ROS1 allosteric inhibitor with AI conjugates to overcome resistance. 针对 MET / RET / ROS1 的变构抑制剂，AI 偶联突破耐药。
β2-AR original mechanism with PAGln/PAA validation loop. β2-AR 原创机制，PAGln/PAA 促衰老验证闭环。
GenTide runs a dual-track model — pipeline assets plus platform services — so early-stage milestones generate real cash flow while the major programs advance. GenTide 采用"管线资产 + 平台服务"双轨模式，让早期里程碑即产生真实现金流， 同时推动核心管线持续前进。
Open the DTBL + Cryo-EM platform to pharma partners under a fee-plus-milestone model. Stable early cash flow while validating platform value and building License-out relationships. 向大型药企开放 DTBL + 冷冻电镜平台，收取服务费 + 里程碑费用。 早期最稳定的现金流来源，同时验证平台价值，为后续授权铺路。
At PCC or IND stage, license regional rights to big pharma for upfront + milestone + royalties. Nav1.8 is the leading License-out candidate targeting US/EU rights. Target: ¥80M–120M near-term, ¥500M–800M mid-term. 在 PCC 或 IND 节点将地区权益授权给大药企，收取预付款 + 里程碑 + 销售分成。 Nav1.8 为首要 License-out 候选。近期目标 8,000 万—1.2 亿元，中期 5—8 亿元。
Retain Greater China rights, partner with US/Europe for co-funded clinical development. Shared risk, shared upside — without diluting our core China market position. 保留大中华区权益，与美国 / 欧洲合作伙伴联合资助临床开发。 风险共担、收益共享，同时保留中国市场核心地位。
Core team assembled · DTBL data pipeline live · GLP-1 & Nav1.8 in-vitro positive data核心团队到位 · DTBL 数据管道上线 · GLP-1 & Nav1.8 体外阳性数据
GLP-1 PCC confirmed · Nav1.8 in-vivo validation · β2-AR PCC announced · DTBL first full closed-loopGLP-1 PCC 确认 · Nav1.8 体内验证阳性 · β2-AR PCC 宣布 · DTBL 首次完整闭环
GLP-1 & Nav1.8 IND-enabling studies launched · First CMC filing drafted · TKI PCC confirmedGLP-1 & Nav1.8 IND 使能研究启动 · 首份 CMC 文件起草 · TKI PCC 确认
Nav1.8 + GLP-1 IND approved (NMPA & FDA dual-track) · Nav1.8 first License-out LOI signedNav1.8 + GLP-1 双 IND 获批（中美双轨）· Nav1.8 首个 License-out LOI 签署
Nav1.8 Phase I enrollment begins · GLP-1 Phase I starts · Major License-out deal closedNav1.8 I 期首例入组 · GLP-1 I 期启动 · 首个重大 License-out 完成
Nav1.8 Phase I/II data · GLP-1 Phase II designed · β2-AR clinical path definedNav1.8 I/II 期数据读出 · GLP-1 II 期方案设计 · β2-AR 临床路径明确